BrainChild Bio, Inc.
PrivateLast Round
Series A
Sep 8, 2026
Total Funding Raised
$116.3M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
BrainChild Bio, Inc. operates in Healthcare & Life Sciences and is based in Seattle, Washington. Its latest recorded funding round was a Series A round in September 2026.
BrainChild Bio, Inc. is a biotechnology company that develops CAR T-cell therapies for the treatment of pediatric and adult central nervous system tumors.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Precision Medicine, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
BrainChild Bio, Inc. Comparables
Compare BrainChild Bio, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Cellevolve Bio | 83% | |
| GlioCART GmbH | 79% | |
| Chimeric Therapeutics Limited | 77% |
For institutional investors. Book with your work email.
BrainChild Bio, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Sep 8, 2026 | ||||
| Grant | Jan 21, 2025 | ||||
| Seed | Dec 5, 2023 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
BrainChild Bio, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Washington Research Foundation Capital | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 8, 2026
$116M round with participation from Seattle Children's Research Institute.
- Apr 17, 2026
Monthly visitors increased 85% MoM.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- expands_offices_toSep 21, 2026
BrainChild Bio, Inc. expands into an office in Washington's Seattle Eastlake neighborhood, where more than half of its 50-plus employees are based, and expects to grow to about 70 to 75 employees over the next year.
- receives_financingSep 8, 2026
BrainChild Bio, Inc. receives $100M in Series A financing as part of a $116 million Series A round on Sep 8th '26 to support a Phase 2 trial of its CAR-T treatment for diffuse intrinsic pontine glioma.
- is_developingSep 8, 2026
On Sep 8th '26, BrainChild Bio, Inc. advances a next-generation CAR T cell therapy platform for tumors of the CNS that integrates synthetic biology, multiplex targeting, approaches to enhance CAR T cell functionality, delivery technologies intended to support durable efficacy, and streamlined design and manufacturing.
- receives_financingSep 8, 2026
On Sep 8th '26, BrainChild Bio, Inc. closes a $116M Series A financing led by an undisclosed private family fund and foundation, with participation from Seattle Children's and WRF Capital, to support its Phase 2 DIPG trial and other CAR T cell therapy programs in Washington and Massachusetts.
- is_developingSep 8, 2026
BrainChild Bio, Inc., a Seattle Children's spinout, is developing BCB-276, a B7-H3-targeted autologous CAR T-cell therapy for pediatric diffuse intrinsic pontine glioma, and recently launches a Phase II study after promising Phase I results in 21 patients in Washington.
For institutional investors. Book with your work email.
BrainChild Bio, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about BrainChild Bio, Inc.'s valuation, stock price, and market status.
Is BrainChild Bio, Inc. a public or private company?
BrainChild Bio, Inc. is a private company.
What is the current stock price of BrainChild Bio, Inc.?
BrainChild Bio, Inc. is a private company, so its shares have no public market price. Caplight tracks BrainChild Bio, Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is BrainChild Bio, Inc. worth (valuation)?
Valuation information for BrainChild Bio, Inc. is not publicly available.
Can I buy BrainChild Bio, Inc. stock?
BrainChild Bio, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was BrainChild Bio, Inc.'s last funding round?
BrainChild Bio, Inc.'s most recent funding round was Series A on September 8, 2026.
Who are the main investors in BrainChild Bio, Inc.?
Key investors in BrainChild Bio, Inc. include Washington Research Foundation Capital.
Will BrainChild Bio, Inc. IPO soon?
No public IPO plans have been announced for BrainChild Bio, Inc..
How can I track BrainChild Bio, Inc. secondary market activity?
Caplight tracks bids, offers, and trades in BrainChild Bio, Inc.'s shares on secondary markets.